Bimekizumab — SCE Dermatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Bimekizumab is a dual IL-17A AND IL-17F inhibitor, whereas Secukinumab only inhibits IL-17A — dual blockade may provide superior efficacy in some patients
Bimekizumab is the first biologic to simultaneously neutralise both IL-17A and IL-17F (bispecific antibody). While IL-17A has been considered the dominant pathogenic cytokine in psoriasis, IL-17F also contributes to keratinocyte activation and neutrophil recruitment. Dual IL-17A/F blockade provides synergistic anti-inflammatory effect. The BE VIVID and BE SURE clinical trials demonstrated higher PASI 100 complete clearance rates for Bimekizumab versus Ustekinumab and Adalimumab. However, the broader IL-17 blockade is associated with higher candidiasis rates (~15%) compared to selective IL-17A inhibitors (~3-4%). NICE has appraised Bimekizumab for moderate-to-severe plaque psoriasis (TA928).
Reference: NICE TA928 Bimekizumab; BAD 2020